MedTrace Logo

Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery

NCT05791721 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-03-30

No results posted yet for this study

Summary

The goal of this clinical trial is to compare preemptive single-dose selective cyclooxygenase 2 (COX-2) inhibitor - etoricoxib and dexamethasone use in systemically healthy patients during the surgical extraction of impacted mandibular third molars. The main questions it aims to answer/evaluate are:

* the level of inflammatory and early wound healing mediators in patients' saliva during early postoperative phase
* clinical postoperative parameters such as pain, swelling and trismus
* patient satisfaction with the treatment
* rescue medication consumed during the postoperative period
* incidence of adverse events

Participants indicated for mandibular third molar surgery will be asked to:

* take premedication (etoricoxib or dexamethasone) before surgical extraction
* provide saliva samples before and following the surgery at regular check-ups
* note the amount of rescue medication taken and pain intensity in different time points
* perform clinical measurements of swelling and trismus at regular check-up visits
* answer the questions about satisfaction and potential adverse events, if occur Researchers will compare preemptive single-dose etoricoxib, preemptive single-dose dexamethasone, and no premedication in impacted mandibular third molar surgery, to see if there are differences in inflammatory response and early wound healing, as well as in clinical postoperative parameters, patient satisfaction with the treatment and incidence of potential adverse events.

Conditions

  • Surgical Wound
  • Post Operative Pain

Interventions

DRUG

Etoricoxib 90 Mg Oral Tablet

Intervention will be applied one hour before surgical extraction of impacted mandibular third molar

DRUG

Dexamethasone 4mg

Intervention will be applied one hour before surgical extraction of impacted mandibular third molar

Sponsors & Collaborators

  • University of Belgrade

    lead OTHER

Principal Investigators

  • Aleksa B Markovic · School of Dental Medicine, University of Belgrade

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-11
Primary Completion
2022-12-26
Completion
2022-12-26

Countries

  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791721 on ClinicalTrials.gov